- Length
- 742 aa
- Mass
- 82.7 kDa
- Annotated
- 2026-04-28
100 papers in source corpus
40 papers cited in narrative
40 extracted findings
Mechanistic narrative
Synthesis pass · prose summary of the discoveries below
Parse failed — see logs
Mechanism profile
Synthesis pass · controlled-vocabulary classification · explore literature graph →
No controlled-vocabulary terms were assigned to this entry.
Evidence
Reading pass · 40 per-paper findings extracted from the source corpus
| Year | Finding | Method | Journal | Conf | PMIDs |
|---|---|---|---|---|---|
| 1992 | SV2A is a 12-transmembrane domain protein homologous to bacterial transporters, specifically to a family of proteins that transport sugars, citrate, and drugs; expression in COS cells yielded intracellular membrane localization consistent with a synaptic vesicle-specific transporter role. | cDNA cloning, sequence analysis, heterologous expression in COS cells, immunolocalization | Science | High | 1355409 1519064 |
| 1992 | SV2A contains two sets of six predicted transmembrane domains: the N-terminal half homologous to glucose/sugar transporters and the C-terminal half homologous to plasma membrane neurotransmitter transporters, suggesting a role in neurotransmitter transport into synaptic vesicles. | Sequence analysis of deduced amino acid sequence | Cell | High | 1355409 |
| 1993 | SV2A is a keratan sulfate proteoglycan; synaptic vesicles contain SV2 in two forms (H and L forms) distinguished by molecular mass, both carrying keratan sulfate glycosaminoglycan chains on the intravesicular side. | Biochemical fractionation of electric organ synaptic vesicles, SDS-PAGE, immunoblotting, glycosaminoglycan characterization | Journal of neurochemistry | High | 7685814 |
| 1994 | SV2A is expressed ubiquitously throughout the brain in all synaptic vesicles; immunoprecipitation showed both SV2A and SV2B can coexist on the same synaptic vesicle. | In situ hybridization, immunohistochemistry, isoform-specific immunoprecipitation followed by Western blot | The Journal of Neuroscience | High | 8083732 |
| 1996 | SV2A directly interacts with synaptotagmin in a calcium-regulated, isoform-specific manner: the interaction is specific to SV2A (not SV2B), is inhibited by calcium with an EC50 of ~10 µM, and is mediated by the cytoplasmic N-terminus of SV2A and the C2B domain of synaptotagmin. | Cross-linking, co-immunoprecipitation, recombinant protein affinity chromatography | The Journal of biological chemistry | High | 8910372 |
| 1996 | SV2A is localized on the membranes of both synaptic vesicles and large dense-cored vesicles (LDCV) in PC12 cells, with a higher SV2:synaptophysin ratio on LDCVs than on synaptic vesicle clusters. | Pre-embedding EM immunocytochemistry with silver-enhanced small gold probe | The Journal of Histochemistry and Cytochemistry | Medium | 8985140 |
| 1999 | SV2A knockout mice develop severe seizures and die within 3 weeks; loss of SV2A reduces action potential-dependent GABAergic neurotransmission in hippocampal CA3 without affecting action potential-independent (miniature) neurotransmission, establishing SV2A as essential for calcium-dependent exocytosis. | Targeted gene disruption (knockout mice), electrophysiology of spontaneous IPSCs in hippocampal slices, synapse ultrastructure analysis | PNAS | High | 10611374 |
| 2000 | SV2A forms a complex with an alpha5-containing laminin (900-kDa laminin) on synaptosomes from electric organ, and purified SV2 binds with high affinity to laminin-1, suggesting SV2 acts as a laminin receptor on the presynaptic plasma membrane. | Co-immunoprecipitation from synaptosomes, affinity chromatography with purified laminin-1, biochemical fractionation | The Journal of biological chemistry | Medium | 10617638 |
| 2001 | SV2A is required to maintain the readily releasable pool (RRP) of vesicles: adrenal chromaffin cells from SV2A knockout mice show a significantly reduced calcium-induced exocytotic burst (operationally defining the RRP), while burst kinetics are normal; loss of SV2A is also associated with fewer SDS-resistant SNARE complexes in brain. | Direct capacitance measurements of exocytosis in chromaffin cells, SDS-PAGE analysis of SNARE complexes | Nature Cell Biology | High | 11483953 |
| 2004 | SV2A is the brain binding site for the antiepileptic drug levetiracetam: photoaffinity labeling of purified synaptic vesicles identifies the ~90 kDa LEV-binding protein as SV2A; brain membranes from SV2A knockout mice show no LEV binding; SV2A expressed in fibroblasts is sufficient for LEV binding; no binding occurs to SV2B or SV2C. | Photoaffinity labeling, tritiated LEV derivative binding assays in SV2A knockout brain membranes, heterologous expression in fibroblasts, correlation between binding affinity and seizure protection | PNAS | High | 15210974 |
| 2005 | All three SV2 isoforms (SV2A, SV2B, SV2C) bind synaptotagmin at a common calcium-inhibited site; additionally, SV2A and SV2C (but not SV2B) possess a distinct N-terminal synaptotagmin-binding site that is stimulated by calcium, mapped to the first 57 amino acids; introduction of the SV2A/C N-terminus into cultured SCG neurons inhibited neurotransmission. | Immunoprecipitation, recombinant protein binding assays, domain mapping, dominant-negative neuronal microinjection | Molecular and Cellular Neurosciences | High | 15866046 |
| 2006 | SV2 (isoforms A, B, and C) is the protein receptor for botulinum neurotoxin A (BoNT/A): BoNT/A binding to hippocampal neurons from SV2A/B knockout mice is abolished and restored by expressing any SV2 isoform; SV2 fragments containing the toxin interaction domain inhibit BoNT/A neuronal binding. | BoNT/A binding assays in SV2 knockout neurons, rescue by viral expression of SV2 isoforms, competitive inhibition with SV2 fragments, reduced BoNT/A sensitivity in SV2B knockout mice | Science | High | 16543415 |
| 2008 | SV2A exists in two major structural conformations in situ: a compact funnel-structure with a pore-like opening toward the cytoplasm, and a more open V-shaped structure with a cleft toward the intravesicular space; levetiracetam binding does not lock SV2A into a specific conformational state. | Protein Tomography of mouse brain tissue | Biochemical and Biophysical Research Communications | Low | 18692481 |
| 2008 | Glycosylated SV2A and SV2B act as protein receptors for BoNT/E: BoNT/E fails to enter SV2A/B knockout neurons; entry is restored by SV2A or SV2B but not SV2C; the fourth luminal domain (LD4) of SV2A/B is sufficient for BoNT/E binding and entry; disruption of an N-glycosylation site (N573Q) in SV2A abolishes BoNT/E entry and reduces BoNT/A entry; gangliosides are also required. | BoNT entry assays in SV2A/B KO neurons, chimeric receptor rescue, site-directed mutagenesis of glycosylation sites, ganglioside depletion/rescue | Molecular Biology of the Cell | High | 18815274 |
| 2009 | SV2 renders primed synaptic vesicles competent for Ca2+-induced exocytosis: deletion of SV2 decreases evoked synaptic responses without changing mini frequency/amplitude, the RRP size, or apparent Ca2+ sensitivity of fusion, indicating SV2 acts at a post-priming step to make vesicles Ca2+/synaptotagmin-responsive; conserved charged residues in transmembrane regions and intravesicular glycosylation are required for normal SV2 folding/trafficking, while the putative synaptotagmin-binding sequence is dispensable. | Electrophysiology in SV2 knockout neurons, rescue experiments with SV2 mutants, analysis of RRP and Ca2+ sensitivity | The Journal of Neuroscience | High | 19176798 |
| 2009 | BoNT/F uses all three isoforms of SV2 (SV2A, B, and C) as protein receptors, as demonstrated by co-precipitation of SV2A, B, and C from Triton-solubilized synaptic vesicles by BoNT/F, and by cross-competition assays and stimulation-dependent uptake in phrenic nerve preparations. | Co-precipitation from synaptic vesicles, phrenic nerve hemidiaphragm assay, cross-competition with recombinant binding fragments, site-directed mutagenesis of ganglioside-binding site | Journal of Neurochemistry | High | 19650874 |
| 2009 | BoNT/F binds glycosylated SV2 through the keratan sulfate moiety; deglycosylation disrupts HCR/F interaction with synaptic vesicle glycoproteins; the HCR/F binding site on SV2 is distinct from that of BoNT/B on synaptotagmin. | Crystal structure of HCR/F and HCR/A, solid-phase array glycan binding, affinity chromatography, deglycosylation enzymes, site-directed mutagenesis | Biochemistry | High | 19476346 |
| 2010 | SV2A regulates synaptotagmin expression and trafficking via a tyrosine-based endocytosis motif (Y46) in its cytoplasmic N-terminus: disruption of this motif (Y46A mutant) prevents SV2A internalization, fails to restore normal synaptotagmin plasma membrane distribution, and reduces binding to clathrin adaptors AP2, EPS15, and amphiphysin 2/Bin1; neurons lacking SV2 have less synaptotagmin in synaptic vesicles. | Mutagenesis, live imaging, in vitro binding assays, immunoisolation of synaptic vesicles from SV2A/B double KO mice, electrophysiology rescue experiments | The Journal of Neuroscience | High | 20410110 |
| 2010 | SV2 regulates neurotransmitter release through at least two independent mechanisms: (1) regulating synaptotagmin expression/trafficking (disrupted by loss of conserved tryptophans W300 and W666 in transmembrane domains 5 and 10), and (2) a separate action unrelated to synaptotagmin (the canonical transporter motif R231Q restores normal synaptic depression without affecting synaptotagmin). | Site-directed mutagenesis of SV2A, electrophysiological rescue in SV2A/B knockout neurons, synaptotagmin expression and internalization assays | American Journal of Physiology – Cell Physiology | High | 20702688 |
| 2010 | SV2 (specifically SV2B) controls key aspects of synaptic function via regulation of presynaptic Ca2+: loss of SV2B elevates both resting and evoked presynaptic Ca2+ signals; short-term reproduction of the Ca2+ phenotype in wild-type terminals reproduces the SV2B-/- secretory phenotype; rescue of Ca2+ phenotype in SV2B-/- neurons relieves all aspects of the secretory phenotype. | Direct presynaptic Ca2+ measurements (fluorescent indicators), capacitance measurements, pharmacological Ca2+ manipulation in the goldfish Mb1 bipolar cell terminal, SV2B knockout mice | Neuron | High | 20620874 |
| 2010 | SV2A and SV2B mediate binding and entry of tetanus neurotoxin into central neurons: tetanus toxin cannot cleave synaptobrevin II in SV2 knockout neurons; entry is rescued by viral expression of SV2A or SV2B; SV2B is preferentially localized to excitatory terminals while SV2A is preferentially at inhibitory terminals in cortical neurons. | Tetanus toxin intoxication assays in SV2 KO neurons, viral rescue, immunolocalization of SV2 isoforms in excitatory vs inhibitory terminals | PLoS Pathogens | High | 21124874 |
| 2011 | SV2 (all three isoforms) serves as the protein receptor for BoNT/D: BoNT/D enters neurons via synaptic vesicle recycling, can bind SV2 in brain detergent extracts, and fails to bind/enter SV2-null neurons; rescue is achieved by any of SV2A, B, or C; BoNT/D uses a mechanism distinct from BoNT/A and BoNT/E since chimeric receptors with BoNT/A/E binding sites cannot mediate BoNT/D entry; gangliosides are also essential. | Toxin binding and intoxication assays in SV2 KO neurons, viral rescue with individual isoforms, co-precipitation from brain extracts, ganglioside depletion | PLoS Pathogens | High | 21483489 |
| 2011 | Levetiracetam reverses the synaptic deficit caused by SV2A overexpression: excess SV2A (~1.5-fold) in autaptic hippocampal neurons reduces release probability and increases synaptotagmin levels; LEV treatment restores normal neurotransmission and normalizes SV2 and synaptotagmin levels at the synapse. | Autaptic hippocampal neuron culture, SV2A-EGFP overexpression, electrophysiology, LEV pharmacology, immunocytochemistry | PLoS One | Medium | 22220214 |
| 2012 | SV2A-deficient (but not SV2B-deficient) mice show increased frequency of spontaneous excitatory postsynaptic currents and decreased frequency/amplitude of spontaneous inhibitory postsynaptic currents in CA1 pyramidal neurons; miniature (action potential-independent) EPSCs and IPSCs are unaffected, indicating SV2A specifically regulates action potential- and Ca2+-dependent transmission. | Whole-cell patch-clamp electrophysiology in hippocampal slices from SV2A KO, SV2B KO, and SV2A/B double KO mice | Journal of Neuroscience Research | High | 22847229 |
| 2012 | N-glycosylation is required for synaptic targeting and function of SV2A: mutation of N-glycosylation sites on SV2A causes only partial mistargeting (N-glycans on SV2A are only partially dispensable), in contrast to synaptophysin where N-glycosylation is essential; glycosylation of synaptotagmin 1 is completely dispensable for SV2 sorting. | Site-directed mutagenesis of all glycosylation sites, pHluorin-tagged protein imaging in cultured neurons from KO mice | The Journal of biological chemistry | High | 22908222 |
| 2013 | UCB1244283 acts as a positive allosteric modulator of SV2A: it increases the affinity of UCB30889 for SV2A fivefold and doubles the total number of binding sites, slows association and dissociation kinetics, and exerts anticonvulsant effects in vivo, indicating that SV2A conformation can be modulated allosterically. | Radioligand binding assays (saturation and competition) on recombinant human SV2A in HEK cells and rat cortex, kinetic binding assays, in vivo audiogenic seizure model | British Journal of Pharmacology | Medium | 23530581 |
| 2013 | The SV2A-binding interface for BoNT/E maps to a site corresponding to the synaptotagmin-binding region of BoNT/B plus an extended surface comprising N- and C-terminal halves of the BoNT/E binding domain; mutations at this interface reduce both SV2 binding and neurotoxicity; a neutralizing antibody inhibits BoNT/E by directly blocking the BoNT/E-SV2 interaction. | Site-directed mutagenesis, pull-down binding assays, phrenic nerve hemidiaphragm neurotoxicity assay, antibody neutralization | The Biochemical Journal | High | 23621114 |
| 2014 | Human SV2A functions as a galactose transporter when expressed in hexose transport-deficient yeast (EBY.VW4000): cells expressing SV2A grow on galactose medium but not other carbon sources; direct measurement confirms galactose uptake; levetiracetam inhibits this galactose-dependent growth, linking drug binding to transporter function. | Heterologous expression in hexose transport-deficient yeast, growth assay on galactose medium, direct radiolabeled galactose uptake measurement, pharmacological inhibition by LEV | The Journal of biological chemistry | High | 25326386 |
| 2015 | SV2A and stonin 2 (Stn2) have overlapping activities in endocytic sorting of synaptotagmin 1 (Syt1) to synaptic vesicles: deletion of either alone causes partial Syt1 missorting, while deletion of both dramatically exacerbates Syt1 loss and missorting, impairing neurotransmission efficacy. | Genetic deletion (SV2A/B KO and Stn2 KO/knockdown), live fluorescence microscopy, electrophysiology in hippocampal synapses | PNAS | High | 26015569 |
| 2015 | Homology modeling and site-directed mutagenesis identified residues lining the levetiracetam binding pocket in SV2A; mutation of D670 leads to complete loss of LEV analog binding, confirming its role in the binding site. | Homology modeling, molecular dynamics simulation, site-directed mutagenesis, radioligand binding assay | PLoS One | Medium | 25692762 |
| 2016 | N-linked glycosylation of SV2C is essential for BoNT/A1 binding and neuronal uptake: the crystal structure (2.0 Å) of the BoNT/A1 receptor-binding domain complexed with glycosylated human SV2C reveals that BoNT/A1 recognizes both the protein moiety and a conserved N-linked glycan on SV2; this glycan is required for potent neurotoxicity. | X-ray crystallography (2.0-Å resolution structure), mutagenesis of glycosylation sites, neuronal binding and toxicity assays | Nature Structural & Molecular Biology | High | 27294781 |
| 2016 | SV2A luminal domain 4 (LD4) binds BoNT/A with isoform-dependent affinity (SV2C >> SV2A > SV2B); binding constant of ~200 nM for BoNT/A to rat SV2C-LD4; binding affinity increases >10-fold at pH 5 (acidic vesicle conditions); the quadrilateral β-helix of SV2C-LD4 pre-exists in solution before toxin binding, unlike the conformational change seen in the BoNT/B-synaptotagmin interaction. | GST pull-down assay, surface plasmon resonance, circular dichroism spectroscopy, pH-dependent binding assays | Toxins | High | 27196927 |
| 2016 | A missense mutation in SV2A (L174Q) specifically reduces depolarization-induced GABA (but not glutamate) release in the hippocampus, reduces synaptotagmin 1 levels, and facilitates kindling epileptogenesis; SV2A is predominantly expressed in GABAergic neurons. | Rat knockin model (Sv2aL174Q), neurochemical measurement of GABA/glutamate release, Western blot for synaptic proteins, kindling model, immunohistochemistry | Scientific Reports | High | 27265781 |
| 2016 | SV2A dysfunction (Sv2aL174Q mutation) elevates seizure susceptibility by preferentially disrupting synaptic GABA release in the amygdala, with SV2A predominantly expressed in GABAergic neurons co-stained for glutamate decarboxylase 1; in vivo microdialysis confirms specific reduction of evoked GABA but not glutamate release. | Rat knockin model, in vivo microdialysis, Fos mapping, immunofluorescence double-labeling | Frontiers in Pharmacology | High | 27471467 |
| 2020 | The epilepsy-linked human SV2A mutation R383Q causes mislocalization of SV2A from synaptic vesicles to the plasma membrane, reduces binding to synaptotagmin-1 (Syt1), and fails to rescue reduced Syt1 expression and dysfunctional activity-dependent Syt1 trafficking in SV2A-depleted neurons. | Molecular replacement strategy in mouse neuronal cultures depleted of endogenous SV2A, live fluorescence imaging of SV2A localization and activity-dependent trafficking, co-immunoprecipitation for Syt1 binding | The Journal of Neuroscience | High | 32341095 |
| 2020 | SV2A coordinates distinct synaptic vesicle recycling rates between excitatory and inhibitory synapses: SV2A is more highly expressed in inhibitory synapses and mediates slower SV recycling (~1.8-fold) in inhibitory vs excitatory terminals, with differential control of synaptotagmin I sorting. | pHluorin-conjugated SV-specific tracers preferentially expressed in excitatory or inhibitory terminals, live imaging of SV recycling kinetics, SV2A knockdown | Progress in Neurobiology | Medium | 32615146 |
| 2020 | Poly-glycine-alanine (GA) dipeptide repeat proteins from C9orf72-ALS/FTD cause reduction in SV2 protein levels and alter Ca2+ influx and synaptic vesicle release; restoring SV2 levels corrects these synaptic phenotypes. | GA mouse model, iPSC-derived neurons from patients, SV2 overexpression rescue, Ca2+ imaging, synaptic vesicle release assays | EMBO Molecular Medicine | Medium | 32347002 |
| 2020 | SV2A expression is regulated post-transcriptionally by miR-133a and miR-218: luciferase reporter assays demonstrate that both miRNAs significantly decrease SV2A 3'UTR-driven expression; transfection of miR-133a and miR-218 reduces endogenous SV2A mRNA and protein in human neuroblastoma cells. | Dual-luciferase reporter assay with SV2A 3'UTR construct, miRNA transfection, RT-qPCR and Western blot of endogenous SV2A | Translational Psychiatry | Medium | 32839459 |
| 2023 | BoNT/A targeted endocytosis into synaptic vesicles requires simultaneous binding to a tripartite plasma membrane nanocluster of polysialoganglioside (PSG), synaptotagmin-1 (Syt1), and SV2; BoNT/A interacts with the preassembled PSG-Syt1 complex and SV2 concurrently, facilitating Syt1-SV2 nanoclustering that controls endocytic sorting into synaptic vesicles. | Live-cell super-resolution imaging, electron microscopy, catalytically inactivated BoNT/A wildtype and receptor-binding-deficient mutants in hippocampal neurons, Syt1 CRISPRi knockdown with SNAP-25 cleavage readout | The EMBO Journal | High | 37226896 |
| 2024 | Cryo-EM structures of full-length SV2A in complex with BoNT/A2 HC and either levetiracetam or brivaracetam reveal: (1) the large fourth luminal domain of SV2A binds BoNT/A2 HC through protein-protein and protein-glycan interactions; (2) LEV and BRV occupy the putative substrate-binding site in an outward-open conformation; (3) a propyl group in BRV creates additional contacts with SV2A explaining its higher affinity than LEV. | Cryo-electron microscopy structure determination of full-length SV2A complexes, label-free spectral shift assay for binding affinity | Nature Communications | High | 38637505 |
Source papers
Stage 0 corpus · 100 papers · ranked by NIH iCite citations
| Year | Title | Journal | Citations | PMID |
|---|---|---|---|---|
| 2004 | The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. | Proceedings of the National Academy of Sciences of the United States of America | 1085 | 15210974 |
| 2006 | SV2 is the protein receptor for botulinum neurotoxin A. | Science (New York, N.Y.) | 579 | 16543415 |
| 1999 | Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). | Proceedings of the National Academy of Sciences of the United States of America | 340 | 10611374 |
| 1994 | Differential expression of synaptic vesicle protein 2 (SV2) isoforms. | The Journal of neuroscience : the official journal of the Society for Neuroscience | 324 | 8083732 |
| 1992 | The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. | Cell | 246 | 1355409 |
| 1992 | SV2, a brain synaptic vesicle protein homologous to bacterial transporters. | Science (New York, N.Y.) | 224 | 1519064 |
| 2008 | Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. | Molecular biology of the cell | 194 | 18815274 |
| 2011 | Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. | European journal of pharmacology | 185 | 21575627 |
| 2008 | Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. | British journal of pharmacology | 184 | 18500360 |
| 2020 | Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. | Nature communications | 179 | 31937764 |
| 2001 | SV2 modulates the size of the readily releasable pool of secretory vesicles. | Nature cell biology | 173 | 11483953 |
| 2009 | SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis. | The Journal of neuroscience : the official journal of the Society for Neuroscience | 141 | 19176798 |
| 2010 | Cotrafficking of SV2 and synaptotagmin at the synapse. | The Journal of neuroscience : the official journal of the Society for Neuroscience | 133 | 20410110 |
| 2007 | SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. | Neuropharmacology | 132 | 18207204 |
| 1996 | Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. | The Journal of biological chemistry | 131 | 8910372 |
| 2009 | Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. | Journal of neurochemistry | 127 | 19650874 |
| 2015 | Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. | Epilepsia | 125 | 26663401 |
| 2006 | Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. | European journal of pharmacology | 122 | 16556440 |
| 2009 | Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. | Biochemistry | 121 | 19476346 |
| 2016 | Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. | Epilepsia | 119 | 26920914 |
| 2010 | SV2 regulates neurotransmitter release via multiple mechanisms. | American journal of physiology. Cell physiology | 117 | 20702688 |
| 2011 | Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. | PLoS pathogens | 112 | 21483489 |
| 2010 | SV2 mediates entry of tetanus neurotoxin into central neurons. | PLoS pathogens | 99 | 21124874 |
| 2010 | SV2 acts via presynaptic calcium to regulate neurotransmitter release. | Neuron | 96 | 20620874 |
| 2007 | Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. | Drug metabolism and disposition: the biological fate of chemicals | 95 | 17908923 |
| 2016 | N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. | Nature structural & molecular biology | 92 | 27294781 |
| 2009 | Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. | Epilepsia | 92 | 19486357 |
| 1993 | The SV2 protein of synaptic vesicles is a keratan sulfate proteoglycan. | Journal of neurochemistry | 92 | 7685814 |
| 2018 | Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue. | European journal of nuclear medicine and molecular imaging | 81 | 30121895 |
| 2005 | SV2A and SV2C contain a unique synaptotagmin-binding site. | Molecular and cellular neurosciences | 73 | 15866046 |
| 1993 | The synaptic vesicle proteins SV2, synaptotagmin and synaptophysin are sorted to separate cellular compartments in CHO fibroblasts. | The Journal of cell biology | 71 | 7901222 |
| 1996 | Subcellular localization of SV2 and other secretory vesicle components in PC12 cells by an efficient method of preembedding EM immunocytochemistry for cell cultures. | The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society | 62 | 8985140 |
| 1994 | Light and electron microscopic analysis of synaptic development in Macaca monkey retina as detected by immunocytochemical labeling for the synaptic vesicle protein, SV2. | The Journal of comparative neurology | 60 | 8144745 |
| 2014 | Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis. | Neuropathology and applied neurobiology | 59 | 23617838 |
| 1989 | Most synaptic vesicles isolated from rat brain carry three membrane proteins, SV2, synaptophysin, and p65. | Journal of neurochemistry | 59 | 2496198 |
| 2015 | Overlapping functions of stonin 2 and SV2 in sorting of the calcium sensor synaptotagmin 1 to synaptic vesicles. | Proceedings of the National Academy of Sciences of the United States of America | 57 | 26015569 |
| 2022 | Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. | Molecular psychiatry | 56 | 35165397 |
| 2016 | Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission. | Scientific reports | 55 | 27265781 |
| 2014 | Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. | ChemMedChem | 55 | 24446373 |
| 2019 | Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers. | Molecular imaging and biology | 54 | 30084043 |
| 2011 | Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. | PloS one | 52 | 22220214 |
| 2016 | A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam. | Journal of Alzheimer's disease : JAD | 50 | 26639968 |
| 2013 | Expression of SV2 isoforms during rodent brain development. | BMC neuroscience | 49 | 23937191 |
| 2005 | SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment. | Journal of cell science | 49 | 16306227 |
| 2007 | Levetiracetam: the first SV2A ligand for the treatment of epilepsy. | Expert opinion on drug discovery | 45 | 23484603 |
| 2000 | The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface. | The Journal of biological chemistry | 45 | 10617638 |
| 2014 | The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae. | The Journal of biological chemistry | 44 | 25326386 |
| 2020 | Synaptic dysfunction induced by glycine-alanine dipeptides in C9orf72-ALS/FTD is rescued by SV2 replenishment. | EMBO molecular medicine | 43 | 32347002 |
| 2012 | Glycosylation is dispensable for sorting of synaptotagmin 1 but is critical for targeting of SV2 and synaptophysin to recycling synaptic vesicles. | The Journal of biological chemistry | 43 | 22908222 |
| 2019 | Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). | European journal of nuclear medicine and molecular imaging | 42 | 31175396 |
| 2015 | Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study. | Molecular imaging and biology | 40 | 25595813 |
| 2014 | Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression. | ACS medicinal chemistry letters | 39 | 25313330 |
| 2013 | Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. | The Biochemical journal | 39 | 23621114 |
| 2009 | Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling. | Biochemical and biophysical research communications | 36 | 19751703 |
| 2020 | Distinct synaptic vesicle recycling in inhibitory nerve terminals is coordinated by SV2A. | Progress in neurobiology | 35 | 32615146 |
| 2012 | Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice. | Journal of neuroscience research | 34 | 22847229 |
| 2010 | The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. | Journal of hepatology | 34 | 20801538 |
| 2013 | Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. | EJNMMI research | 33 | 23647774 |
| 1993 | Conservation of the amino acid sequence of SV2, a transmembrane transporter in synaptic vesicles and endocrine cells. | Gene | 33 | 8299963 |
| 2012 | Analysis of Synaptotagmin, SV2, and Rab3 Expression in Cortical Glutamatergic and GABAergic Axon Terminals. | Frontiers in cellular neuroscience | 32 | 22275882 |
| 2019 | Increased Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Postmortem Frontal Cortex of Alzheimer's Disease Patients. | Frontiers in cellular neuroscience | 31 | 31866830 |
| 2013 | Amyloid beta a4 precursor protein-binding family B member 1 (FE65) interactomics revealed synaptic vesicle glycoprotein 2A (SV2A) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) as new binding proteins in the human brain. | Molecular & cellular proteomics : MCP | 31 | 24284412 |
| 2011 | Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model. | PloS one | 31 | 22046416 |
| 2011 | Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. | Journal of pain research | 31 | 22090803 |
| 2018 | SV2: accurate structural variation genotyping and de novo mutation detection from whole genomes. | Bioinformatics (Oxford, England) | 30 | 29300834 |
| 2020 | In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism | 29 | 32538280 |
| 2016 | Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin. | Toxins | 29 | 27196927 |
| 1998 | Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. | Journal of neurochemistry | 28 | 9648885 |
| 2020 | An Epilepsy-Associated SV2A Mutation Disrupts Synaptotagmin-1 Expression and Activity-Dependent Trafficking. | The Journal of neuroscience : the official journal of the Society for Neuroscience | 26 | 32341095 |
| 2016 | A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release. | Frontiers in pharmacology | 26 | 27471467 |
| 2008 | No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. | Epilepsy research | 26 | 18977120 |
| 2024 | Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J. | Alzheimer's & dementia : the journal of the Alzheimer's Association | 25 | 38363009 |
| 2011 | Insecticidal potency of bacterial species Bacillus thuringiensis SV2 and Serratia nematodiphila SV6 against larvae of mosquito species Aedes aegypti, Anopheles stephensi, and Culex quinquefasciatus. | Parasitology research | 25 | 22065062 |
| 2008 | Visualization of SV2A conformations in situ by the use of Protein Tomography. | Biochemical and biophysical research communications | 25 | 18692481 |
| 2023 | Presynaptic targeting of botulinum neurotoxin type A requires a tripartite PSG-Syt1-SV2 plasma membrane nanocluster for synaptic vesicle entry. | The EMBO journal | 24 | 37226896 |
| 2020 | Quantification of SV2A Binding in Rodent Brain Using [18F]SynVesT-1 and PET Imaging. | Molecular imaging and biology | 24 | 33258040 |
| 2017 | Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis. | CNS & neurological disorders drug targets | 24 | 28393712 |
| 2015 | Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis. | PloS one | 23 | 25692762 |
| 2013 | Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. | British journal of pharmacology | 23 | 23530581 |
| 2012 | Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus. | Neuroscience letters | 23 | 22266237 |
| 2002 | Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas. | The Journal of pathology | 23 | 11748641 |
| 1996 | Mapping the innervation of the bronchial tree in fetal and postnatal pig lung using antibodies to PGP 9.5 and SV2. | American journal of respiratory cell and molecular biology | 23 | 8969263 |
| 2019 | Differential expression of SV2A in hippocampal glutamatergic and GABAergic terminals during postnatal development. | Brain research | 22 | 30905653 |
| 2018 | Expression of KLF6-SV2 in colorectal cancer and its impact on proliferation and apoptosis. | European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) | 22 | 29084019 |
| 2002 | Neoplastic transformation of human lung fibroblast MRC-5 SV2 cells induced by benzo[a]pyrene and confluence culture. | Cancer research | 22 | 12183415 |
| 2020 | Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy. | Molecular imaging and biology | 21 | 32206990 |
| 2023 | Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil. | Neuroscience bulletin | 20 | 37897555 |
| 2024 | SV2A PET imaging in human neurodegenerative diseases. | Frontiers in aging neuroscience | 18 | 38699560 |
| 2014 | Hippocampal low-frequency stimulation increased SV2A expression and inhibited the seizure degree in pharmacoresistant amygdala-kindling epileptic rats. | Epilepsy research | 18 | 25205164 |
| 2024 | Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment. | Alzheimer's & dementia : the journal of the Alzheimer's Association | 17 | 38634334 |
| 2019 | Mode of seizure inhibition by sodium channel blockers, an SV2A ligand, and an AMPA receptor antagonist in a rat amygdala kindling model. | Epilepsy research | 16 | 31035244 |
| 2023 | Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease. | Movement disorders : official journal of the Movement Disorder Society | 15 | 37382295 |
| 2024 | Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A. | Nature communications | 14 | 38637505 |
| 2021 | Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer. | International journal of molecular sciences | 14 | 34884893 |
| 2020 | Integration of postmortem amygdala expression profiling, GWAS, and functional cell culture assays: neuroticism-associated synaptic vesicle glycoprotein 2A (SV2A) gene is regulated by miR-133a and miR-218. | Translational psychiatry | 14 | 32839459 |
| 2019 | Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation. | Clinical neurology and neurosurgery | 14 | 31005049 |
| 2016 | Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy. | PloS one | 14 | 27861538 |
| 2018 | Preparation of 99mTc-levetiracetam intranasal microemulsion as the first radiotracer for SPECT imaging of the Synaptic Vesicle Protein SV2A. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences | 13 | 29787786 |
| 2012 | Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia. | Schizophrenia research | 13 | 23017826 |
| 2009 | SV2 frustrating exocytosis at the semi-diffusor synapse. | Synapse (New York, N.Y.) | 13 | 19140166 |